MMRGlobal, Inc. (fka MMRF)

[RUBY1100]

MMRF Blog Update April 12

Stay Tuned For More On MMRF Biotech Assets

April 12th, 2010

In addition to our Personal Health Record and Professional Health IT products and services, MMR continues to learn more about its pre-merger Favrille assets, the value they can bring to our shareholders and the secrets they might hold for the benefit of Cancer research.

As discussed in our recent March 2nd news release, MMR has been informed that it may have opportunities to enter into relationships that could lead to a re-interpretation of the previous Favrille cancer vaccine trials. Through May of 2008 pre-merger Favrille had spent more than 140 million dollars on the creation and development of intellectual property. This IP includes clinical trials data from patient samples, patents and other assets. We look forward to sharing more information about these opportunities with you in the near future.

Based on continued discussions with the company’s biotech consultants and others we now understand that the IP may unlock ways to create “custom-made” cancer vaccines and other opportunities in cancer research. We understand that these assets could be of value to biopharmaceutical companies, academic institutions, research organizations and others.

When the Robert H. Lorsch Family Pavilion was built at The California Science Center http://tinyurl.com/y8nyxht, I had hoped it would become a gateway for discovery by children who passed through its entrance. Maybe some of those kids will use these assets to make a difference in the fight against Cancer. When I was growing up in Chicago I was not a very good student yet my favorite childhood place was the Museum of Science and Industry. I never understood why. There must be truth in the line from the book Illusions, by Richard Bach. “We teach best, what we need to learn the most”.

Robert H. “Bob” Lorsch,CEO MMR Information Systems Inc

Statements in this blog that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding the Company’s assets including but not limited to its primary Health IT businesses, data from Specifid/Favid vaccine and clinical trials or it’s ability to enter into a successful agreement to enter into a relationship for a re-interpretation of the previous Favrille cancer vaccine trials and/or receive the necessary regulatory approvals for such trials the outcomes of which may not be known for some time. These includes, but are not limited to, risks and uncertainties related to the development and approval of biotechnology product candidates and Health IT products and services as discussed in the Company’s filings with the Securities and Exchange Commission. MMR Information Systems, Inc. (MMRF), Inc. is providing this information as of the date of this blog and, except as required by law, does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.